These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11363697)

  • 1. Saquinavir plus ddC reduces deaths by more than two-thirds.
    J Int Assoc Physicians AIDS Care; 1996 Jun; 2(6):51. PubMed ID: 11363697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saquinavir: combination shows survival benefit; new formulation trial recruiting.
    AIDS Treat News; 1996 May; (no 246):1-2. PubMed ID: 11363484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saquinavir prolongs survival and slows disease progression.
    BETA; 1996 Jun; ():6. PubMed ID: 11363649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitors and prevention of cross resistance.
    Levin J
    AIDS Treat News; 1995 Oct; (no 232):1-3. PubMed ID: 11362875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent new AIDS drugs underscore promise of combination therapy.
    AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saquinavir thwarts resistance.
    AIDS Alert; 1995 Oct; 10(10):123. PubMed ID: 11362782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA triple header. Food and Drug Administration.
    Smart T
    GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritonavir: first to prolong survival.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):38-44. PubMed ID: 11363517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saquinavir gets accelerated approval.
    McGuire S
    Posit Aware; 1996; 7(1):8. PubMed ID: 11363135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No tease this time--pros and cons of a long-awaited anti-HIV drug.
    Chang HE
    Posit Aware; 1996; 7(1):18-20. PubMed ID: 11363118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roche submits NDA for Invirase.
    J Int Assoc Physicians AIDS Care; 1995 Sep; 1(8):37-8. PubMed ID: 11362796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinder, gentler ddC... for $7,200 a year.
    GMHC Treat Issues; 1995 Dec; 9(12):2. PubMed ID: 11362996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease inhibitor update: treatment combination strategies.
    Mascolini M
    AIDS Treat News; 1996 Jan; (no 239):3. PubMed ID: 11363085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3TC and saquinavir: we need them now.
    Baker R
    BETA; 1995 Sep; ():3. PubMed ID: 11362889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.
    Roberts NA
    AIDS; 1995 Dec; 9 Suppl 2():27-S32. PubMed ID: 8775804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug companies seek trial participants.
    AIDS Alert; 1995 Jun; 10(6):82. PubMed ID: 11362432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two protease inhibitors given high expectations.
    AIDS Alert; 1996 Jun; 11(6):63. PubMed ID: 11363541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saquinavir: major study shows survival benefit in treatment-naive patients.
    James JS
    AIDS Treat News; 1997 Jul; (No 274):6. PubMed ID: 11364463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lottery opens 2,000 slots for protease trial.
    AIDS Alert; 1995 Nov; 10(11):144. PubMed ID: 11362929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS
    AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.